Posted by Michael Wonder on 21 Jan 2020
European Commission approves Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are transplant eligible
20 January 2020 - Janssen announced today that the European Commission has granted marketing authorisation for Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
This approval is based on results from Part one of the Phase 3 CASSIOPEIA (MMY3006) study, published in The Lancet5 in June 2019 and presented at the 2019 American Society of Clinical Oncology Meeting.
